Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment

Raddadi, Ali; Jfri, Abdulhadi; Samarghandi, Sahal; Matury, Nesreen; Habibullah, Taha; Alfarshoti, Majed; Ahmad, Mahmood

doi:10.1016/j.jdds.2015.05.002

Cited by 15 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 In present study, patients with lesions over the thigh fold and gluteal region has more impaired quality of life than other sites, whereas the exposed sites in DLQI studies on acne and psoriasis lead to more impaired quality of life. 9,12,13 11.3% and 52.7% cases had extremely large and very large impact in QOL scoring in this study which can be attributed to the most common site of involvement i.e. gluteal region and thigh folds, in combination with irregular treatment, poor hygiene.…”

Section: Discussionmentioning

confidence: 67%

“…19,26 The mean DLQI score increased as age of the patients advances, which also includes loss of self-confidence and low self-esteem similar DLQI scoring was seen in few other dermatoses like alopecia areata, acne and psoriasis. [6][7][8][9]12,13 However in DLQI study of vitiligo poor quality of life is observed in young patients. 11 In present study, patients with lesions over the thigh fold and gluteal region has more impaired quality of life than other sites, whereas the exposed sites in DLQI studies on acne and psoriasis lead to more impaired quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…3 Though, there are few studies of assessment of DLQI in various dermatoses like alopecia areata, acne vulgaris, atopic dermatitis, vitiligo vulgaris, psoriasis vulgaris and photodermatosis, but no studies available in the literature on the impact of dermatophytosis on the quality of life (QOL). [6][7][8][9][10][11][12][13][14] Hence to assess the quality of life in these patients, this study is being undertaken.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Dermatology life quality index in patients with persisting and recurrent dermatophytoses

et al. 2019

View full text Add to dashboard Cite

Background: Dermatophytosis is the most common fungal infection, which has recurrent and persisting course because of topical steroid abuse, irregular treatment and poor hygiene. Dermatology life quality index (DLQI) is a questionnaire based survey method to assess the impact and severity of many dermatology specific diseases and infections. There is paucity in the literature on the impact of dermatophytosis on the quality of life (Qol). The aim of the study was to assess the impact of dermatophytosis and its sequelae on quality of life.Methods: A total of 186 patients with recurrent and persistent dermatophytosis were selected for Qol questionnaire for a period of six months and statistical analysis was performed using t test to determine the impact of dermatophytosis on Qol.Results: Male to female ratio was 2.7:1, most cases were between 25 to 45 years age group. Thigh fold and gluteal region were the most common sites involved. Mean DLQI score was 12.7. The DLQI scores were statistically influenced by age of the patient, duration of the infection and site of involvement.Conclusions: This study revealed significant impairment of Qol in dermatophytosis patients. Assurance and counselling along with early and prompt treatment plays a significant role in reducing disease related psychosocial sequelae and increase the efficacy of treatment.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Dermatology life quality index in patients with persisting and recurrent dermatophytoses

et al. 2019

View full text Add to dashboard Cite

show abstract

“…So DLQI is used for measurement in term of patient's quality of life but also effectiveness of drugs on health of patients . 18,19 This study showed favorable effects on progress of disease and health related quality of life as assessed by PASI (p value = 0.0001) and DLQI (p value = 0.001). PASI was decreased to 2.806 ± 0.183 at end of study from 11.277±0.729.…”

Section: Discussionmentioning

confidence: 68%

Remarkable effect of topical betamethasone valerate 0.1% on progress of psoriasis disease.

Asad

Rizvi

Azhar³

2019

TPMJ

View full text Add to dashboard Cite

ABSTRACT… Psoriasis is immuno-inflammatory condition devouring huge negative impact on patient's life as compare to other diseases. Topical regimen is the standard treatment for mild to moderate psoriasis disease. The data of effectiveness of Betamethasone Valerate 0.1% on large number of psoriatic patients were being deficient. Objectives: This study evaluates the Topical Betamethasone Valerate 0.1%impact on patient's life in relation to efficacy and safety. Design: Interventional experimental study. Setting: Study was carried out Basic medical sciences institute (BMSI) alliance with Dermatology Department JPMC, Karachi. Period: June 2013 to June 2016. Methods: 75 chronic plaque type psoriatic patients prescribed Betamethasone Valerate (0.1%) topically along with placebo for 6 months once daily (one week interval after three week application). The therapeutic effectiveness and safety of studied drug were assessed by means of PASI, DLQI and hsCRP. The results analyzed by using repeated ANOVA. Results: Results revealed when camparasion of all parametres with base line they were significantly reduced as mean percentage change were 75.001±0.0563, 72.215±3.17and 33.692±7.980 for PASI, DLQI and hsCRP respectively at the end of study. Safety profile of therapy showed non-significant outcomes. Conclusion: Betamethasone valerate 0.1% is better treatment option in mild to moderate psoriatic patients to improve quality of life and decrease disease severity.

show abstract

“…PASI score <10 defined psoriasis as mild, between 10 and 20 as moderate, and >20 as severe. 15 A group of 50 healthy subjects of matched age and sex were included as a control group who were taken from amongst volunteering hospital staff and relatives. All participants signed an informed consent before being included in the study.…”

Section: Methodsmentioning

confidence: 99%

Hyperuricemia and Serum ADA Levels in Psoriasis and their Correlation to Severity of Disease

Nadeem¹,

Shah²,

Waseem³

et al. 2019

IJCMR

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic inflammatory autoimmune disease characterized by hyperproliferation of keratinocytes with multifactorial pathogenesis including genetic, and environmental factors. The aim of this study was to evaluate serum ADA, SUA, and ESR in psoriatic patients and their correlations with PASI score. Material and methods: Our study was a case-control study. The sample size was calculated using the Cochran formula and 50 patients of psoriasis who attended the out patient clinic at SMHS and Government medical college, srinagar were included in the study. These patients were divided according to PASI scores into three groups (mild, moderate, and severe). PASI score <10 defined psoriasis as mild, between 10 and 20 as moderate, and >20 as severe. A group of 50 healthy subjects of matched age and sex were included as a control group who were taken from amongst volunteering hospital staff and relatives. Results: This study included 50 psoriatic patients classified according to PASI score into mild, moderate, and severe psoriatic group and 50 age and sex matched controls. Out of these four patients had mild psoriasis, twelve patients had moderate psoriasis and thirty four patients had severe psoriasis according to PASI. Fifty healthy subjects were included as a control group. There were no statistically significant differences of age and sex between different patients and the control group. Conclusion: ESR, Serum Uric Acid and serum adenosine deaminase levels are significantly raised in patients with psoriasis. However there was no association with severity of disease in these patients, however, larger studies are needed to elucidate the mechanism and whether this hyperuricemia predisposes these patients to gout and increased risk of cardiovascular disease.

show abstract

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment

Cited by 15 publications

References 15 publications

Dermatology life quality index in patients with persisting and recurrent dermatophytoses

Dermatology life quality index in patients with persisting and recurrent dermatophytoses

Remarkable effect of topical betamethasone valerate 0.1% on progress of psoriasis disease.

Hyperuricemia and Serum ADA Levels in Psoriasis and their Correlation to Severity of Disease

Contact Info

Product

Resources

About